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What is already known about the subject? 
 
Drug safety in paediatric medication is a public health concern. According to previous studies, the 
incidence of adverse drug reactions (ADRs) varies greatly from 0.7% to 2.7% among paediatric 
outpatients and from 2.6% to 18.1% among paediatric inpatients. Little has been reported on the risks 
of drug use in the general child population. 
 
What this study adds 
 
Our study showed that the prevalence of perceived ADRs in Germany was 0.9% among non-
institutionalized children in general and 1.7% among children who had used at least one medicine 
within the 7 days before the medical interview. Perceived ADRs in the general child population were 
clustered with gastrointestinal disorders and subcutaneous tissue disorders. They appeared to be mild 
and at the lower limits of the range reported in other studies. Health surveys covering the use of a 
diverse range of drugs might be suitable for computing ADR prevalence and for identifying risk factors 




Aims: Little has been reported on the risks of drug use in the general child population. This study 
investigated perceived adverse drug reactions (ADRs) among non-institutionalized children in 
Germany. 
 
Methods: All medicines used in the last 7 days before the medical interview were recorded among the 
17 450 children aged 0–17 years who participated in the 2003–06 German Health Interview and 
Examination Survey for Children and Adolescents (KiGGS). Perceived ADRs were reported by the 
children’s parents and confirmed by trained medical professionals during the medical interview. 
 
Results: One hundred and fifty-seven medicines were involved in the occurrence of 198 perceived 
ADRs in 153 patients. This corresponded to 1.1% of total used drugs, 0.9% (95% confidence intervals 
0.7, 1.1%) of all children, and 1.7% (1.4, 2.1%) of children treated with medications. About 40% of all 
perceived ADRs involved gastrointestinal disorders and 16% involved skin tissue disorders. Perceived 
ADRs were most frequently reported in relation to drugs acting on the nervous system (25.8%), 
followed by systemic anti-infectives (18.7%) and drugs acting on the respiratory system (16.2%). Risk 
factors for perceived ADRs included older age groups, polypharmacy (≥2) and a poor health status. 
 
Conclusion: Perceived ADRs in the general child population were clustered with gastrointestinal 
disorders and subcutaneous tissue disorders. They appeared to be mild and at the lower limits of the 
range reported in other studies. Health surveys covering the use of a diverse range of drugs might be 
suitable for computing ADR prevalence and identifying risk factors among non-institutionalized 
















For a long time now, adverse drug reactions (ADRs) have been recognized as one of the main causes 
of paediatric morbidity in the USA and some European countries [1–3]. Many studies on paediatric 
ADR occurrence have been published since then. Most of them are based on an analysis of data on 
hospitalized children [4–9], outpatient paediatric clinics or drug consumption [10–14].Results on ADR 
incidence vary greatly in these studies, between 0.7% [10] and 2.7% [11] for paediatric outpatients 
and between 2.6% [10] and 18.1% [9] for paediatric inpatients. An earlier meta-analysis of 17 
prospective studies published between 1973 and 2000 estimated that the overall incidence of ADRs 
was 1.46% for paediatric outpatients and 9.53% for paediatric inpatients [15] and a recent 
metaanalysis of eight prospective studies published between 2001 and 2007 reported weighted 
average ADR incidence rates of 1.0% for paediatric outpatients and 10.9% for paediatric inpatients 
[16].  
 
In Germany, ADR incidence has been investigated by means of intensive monitoring in hospital. In a 
10-bed paediatric isolation ward of a German university hospital in Erlangen, the ADR incidence was 
estimated at 17.4–21.5% [17–19] using this method. Another study conducted in the HELIOS Klinikum 
Wuppertal teaching hospital reported that 14.1% of inpatient children experienced an ADR over a 
period of 3 months [20]. These studies were conducted in paediatric wards. Few results have been 
reported in Germany from non-clinical settings on epidemiological aspects of the risks of paediatric 
drug use. An early regional ADR monitoring programme in the federal state of Brandenburg estimated 
that ADR incidence was approximately 1% among children given medications [21]. This study was 
conducted 10 years ago. More up-to-date population-representative national data on 
noninstitutionalized children not necessarily using medical services have so far been very rare both in 
Germany and worldwide. Against this background, we investigated the perceived ADRs reported by 
children’s parents among non-institutionalized children and adolescents in Germany using the drug-






Data source and study population 
 
The German KiGGS survey was conducted by the Robert Koch Institute from 2003 to 2006. KiGGS 
investigated 0- to 17-year-old children and adolescents usually resident in Germany with the aim of 
providing comprehensive and representative data on their health status [14].  
 
The design, sampling strategy and study protocol of KiGGS have been described in detail elsewhere 
[14]. Briefly, two-stage sampling procedures were applied. In the first stage, a sample of 167 German 
municipalities (112 in the formerWest Germany, 55 in the former East Germany) was drawn which was 
representative of municipality sizes and structures inGermany.In the second stage,the addresses of all 
28 299 children and adolescents were chosen randomly from the local population registers. Children 
and adolescents 
with a foreign nationality were also included. Excluded were children who were currently in institutions 
such as hospitals, medical and nursing stations [22]. The overall percentage of non-deliverable survey 
contacts was 5.3%.The final survey sample included 17 641 children and adolescents with a response 
rate 66.6% [22]. One hundred and ninety-one children did not provide drug-use data and were 
therefore excluded fromthe present study,resulting in a studypopulation of 17 450 children (8880 
boys,8570 girls; see Table 1). All survey participants were informed of the purpose of the study and 
other relevant concerns.Informed consent was obtained prior to the medical examination either from 
the children’s parents or from the children themselves if they were over the age of 14 years [14]. 
 
 
Data collection and assessment 
 
All the children’s parents/guardians and all children aged 11 years or older were asked to fill in a 
standard parents’ or children’s questionnaire. These questionnaires were used to collect information 
on socio-demographic data, family backgrounds, parents-rated children’s health status, and health-
  
related living conditions and behaviour patterns. In addition, trained physicians conducted a 
standardized, computer-assisted personal interview with the children’s parents and the children 
themselves on medical history, health problems and all medicines used within the 7 days prior to the 
interview [23]. Parental social status was defined as lower, intermediate or upper according to the total 
scores of a composite social-status index integrating the parents’ levels of education, household 
incomes and professions [24]. Children who themselves (or whose mother/father) did not have 
German nationality or were not born in Germany were defined as having an immigration 
background [25].  
 
Medicine use was investigated by asking the following question: 
‘Has your child taken any medicines in the last 7 days? Please also mention the use of any ointments, 
linaments, contraceptive pills, vitamin and mineral supplements, medicinal teas, herbal medicines or 
homoeopathic medicines’.  
 
Children aged 14 years and older were encouraged to add data on the use of medicines themselves. 
All prescription or over-the-counter (OTC) medicines used in the 7 days before the interview were 
recorded in the answers to this question. The definition of ‘medicines’ here was broader than that used 
by the German Medicines Act [26].  
 
We collected the following information on every medicine mentioned by parents or the children 
themselves:  
 
brand name: as free text; 
indications: as free text;  
form of administration: i.e. tablets, dragees, drops, ointments, injections, liniments, etc.;  
frequency of intake: ‘several times a day’, ‘every day’, ‘regularly but not daily’ or ‘every week’;  
origin of the medicine:‘prescribed by a doctor’,‘prescribed by a non-medical practitioner’,‘bought over 
the counter’,or ‘obtained from other sources’;  
duration of use: ‘<1 week’, ‘1–4 weeks’, ‘1–12 months’ or ‘1 year or longer’;  
improvement in the condition(s) treated: ‘great’, ‘partial’, ‘not much’, ‘not at all’ or ‘does not apply’;  
 
We also asked the children’s parents or the children themselves whether or not the medicine used 
was well tolerated and to describe the degree of tolerability (‘very good/good’,‘partial’,‘not good’or 
‘poor’). Another question was whether any ADRs/side effects were noticed following the use of the 
medicine (‘yes’or ‘no’). If the answer was‘yes’, 
the ADRs/side effects reported were documented and confirmed informally by interviews conducted by 
physicians with medical knowledge. No standardized causality/ severity assessment was made on the 
reported ADRs, however. 
 
The free texts on medicine brand names were coded according to WHO ATC (Anatomical 
Therapeutic-Chemical) codes [27] as follows: A00 (alimentary system and metabolism), B00 (blood 
and blood-forming organs), C00 (cardiovascular system), D00 (dermatologicals), G00 (genito-urinary 
system and sex hormones), H00 (systemic hormonal preparations excluding sex hormones and 
insulin), J00 (anti-infectives for systemic use), L00 (antineoplastic and immunmodulating agents), M00 
(musculoskeletal system), N00 (nervous system), P00 (antiparasitic products, insecticides and 
repellents), R00 (respiratory system), S00 (sensory organs) and V00 (various). Homoeopathic 
preparations, which were commonly used among children and adolescents in Germany [28], were 
given an additional new code ‘Z00’ as they were not covered by the ATC classification system. 
Indications of medicines were coded according to WHO ICD-10 [29] and ADRs according to MedDRA 
(Medical Dictionary for Regulatory Activities, version 10.1); the so-called ‘preferred terms’ [PT System 





All statistical analyses were performed using SPSS statistical software (release 17.0).Descriptive 
statistics were used to analyze characteristics of the study population including the prevalence of 
perceived ADRs. Associations of the perceived ADRs with socio-demographic and healthrelated 
characteristicswere quantified by using odds ratios (OR) and their 95% confidence intervals (95% CIs), 
which were derived from multiple logistic regression models among children who had taken 
medications.The complex sample method was used to obtain the 95% CIs by the SPSS procedure 
[22]. Group differences were considered statistically significant if a P value was less than 0.05 or if 
  





Table 1 lists the main characteristics of the study sample by gender.The vast majority of boys and girls 
had a good/very good health status, came from families with no immigration background and resided 
in the formerWest Germany and in cities. Nearly half of boys and girls lived in a family with an 
intermediate social status, one quarter, respectively, in a family with a low or high social status.No 
significant difference was found between boys and girls with regard to these characteristics. 
 
Eight thousand eight hundred and ninety-nine children (51%) had used at least one medicine during 
the last 7 days before the interview (Table 1), with girls showing a higher proportion than boys (P < 
0.05). One hundred and fifty-three children reported perceived ADRs, corresponding to a population 
prevalence rate of 0.9% (95% CIs 0.7, 1.1%) with no difference between boys and girls (P =0.835). 
Among children who used at least one medicine, the prevalence of perceived ADRs was 1.7% (1.4, 
2.1%) (data not shown in Table 1).  
 
Among children who had used medications, no significant difference in the prevalence of perceived 
ADRs was found in subgroups stratified by gender, regions of residence, immigration background and 
parental social status (Table 2).Along with age,the prevalence of perceived ADRs showed a J-shape 
curve; the highest rate was found in the 14–17 year age group, the lowest in the 3–6 and 7–10 year 
age groups (P < 0.001). A significant difference was also found in the number of concomitantly used 
medicines and the children’s parents-rated health status. The prevalence of perceived ADRs was 
seven times higher in children using four or more medicines than in children using only one. This 
association was found in both sexes and all age groups (data not shown). The difference was 
significant within users of one to four medicines, but disappeared when stratified by age and sex (data 
not shown). The prevalence of perceived ADRs was more than nine times higher among children with 
a bad/very bad health status than among children with a good/very good health status. The risks of 
perceived ADRs were confirmed in the multivariate regression analysis. The interaction between the 
number of drugs and children’s health status was not statistically significant (data not shown in Table 
2).  
 
A total of 14 588 medicines were recorded in the study sample; 157 medicines (1.1%) were reportedly 
involved in the occurrence of perceived ADRs (Table 3). A significantly lower proportion was found 
among the non-prescription medicines, medicines obtained from other sources, and preparations used 
for a short term (<1 week) or irregularly. By contrast, a significantly higher proportion was found in 
prescription medicines, medicines used for a medium period (from 1 week to 12 months) and in 
medicines that were used regularly.  
 
Medicines from the classes N00, J00, R00, G00, D00 and A00 (representing 82% of the total 
medicines) covered the 
vast majority of suspected drugs (Table 4). The proportion of suspected drugs in each of these 
medication classes varied from 0.4% for A00 to 5.7% for J00.The same was true for the medications in 
the subgroups.The highest proportion was recorded in psychoanaleptics (12.1%, particularly 
methylphenidate 11.9%), followed by antibiotics 6.0% and contraceptives 2.8%. Although P00 
(antiparasitic products, insecticides and repellents) showed the highest proportion of 10%, the number 
of medicines in this class was very low, being only 20 (Table 4).  
 
Most perceived ADRs were recorded in drugs acting on the nervous system (N00), followed by 
systemic antiinfectives (J00), drugs acting on the respiratory system (R00), and drugs acting on the 
genitourinary system and sex hormones (G00) (Table 5).According toMedDRA terminology, 40.4% of 
all perceived ADRs related to gastrointestinal 
disorders such as nausea, vomiting and diarrhoea, while 16.2% were skin and subcutaneous tissue 










In a population-representative sample of children aged 0 to 17 years,we found that 0.9% (1.7% of 
children who had used medications in the last 7 days) reportedly experienced an ADR. Similar findings 
have been reported in previous pharmacovigilance studies conducted among children in Germany and 
other European countries.  
 
A 3 month German ADR monitoring project estimated the incidence of mild to moderate ADRs as 
about 1% in children who had been given medications [21]. An Italian active ADR monitoring program 
reported an ADR incidence rate of 15.1 per 1000 children [3]. A prospective 1 week monitoring study 
in France found that 1.53% of children consulted a regional hospital and 0.67% a private paediatrician 
because of ADRs [10]. Another French prospective pharmacovigilance survey of drug prescribing by 
office-based paediatricians reported an ADR incidence rate of 1.41% [32].The results of two meta-
analysis studies estimated that the ADR incidence rate was 1.0 (95% CI 0.3, 1.7) for outpatient 
children [16] and 1.46% (95% CI 0.7, 3.03) for children undergoing outpatient care [15]. Our finding on 
the prevalence of perceived ADRs was well below the 95% CIs of the two studies [15, 16].However, 
the children in our study were non-institutionalized and sampled from the general child population; 
most of them were in good/very good health.Since most outpatient children 
were being treated for a specific condition and more likely to be given medications, there was a 
greater possibility of ADRs. This may be one of the reasons why the prevalence rates of perceived 
ADRs in the total sample and among drug users were close to the lower and upper 95% CIs, 
respectively, of the two meta-analysis studies [15, 16].  
 
In the Italian ADR monitoring programme, the highest ADR incidence rate was found in the youngest 
infant group, the lowest among children aged 8 to 14 years [3]. In a retrospective study conducted in 
Singapore, in which age and sex were independent ADR risk factors among hospitalized children, 
ADRs were more likely to occur at higher ages and among boys [33]. Data from the Sweden Medical 
Products Agency on the mandatory reporting of ADRs also showed a higher ADR frequency among 
boys than among girls over the period from 1987 to 2001, particularly among children under 5 years of 
age [34]. Our study, however, found no difference between boys and girls, but a significant difference 
between age groups, which largely showed a J-shaped curve, the highest rate being found in the 14–
17 year age group.This may be due 
to the fact that many ADRs reported in our study related to oral contraceptives and Ritalin, which were 
used mainly by older adolescents.  
 
Polypharmacy was a well-established ADR risk factor in both adult and child patients [15, 35]. As the 
number of concomitantly used drugs increases, so does the likelihood of drug–drug interactions, 
leading to a greater possibility of ADRs.We found a significant correlation between perceived ADRs 
and the number of concomitantly used drugs. This finding has been consistently observed previously 
in a prospective study of spontaneous ADR reporting among 
hospitalized children in Spain [6], in an ADR monitoring study of outpatient infant and preschool 
children in the Zagreb region [11] and in a retrospective study in Singapore [33].Self-rated health 
status was an important indicator of morbidity; a poor state of health may imply a greater possibility of 
medication use [36] and therefore be a predictive risk factor of ADRs.  
 
In our study gastrointestinal disorders such as nausea, vomiting and diarrhoea accounted for 40% of 
perceived ADRs, followed by skin/subcutaneous tissue disorders and general disorders/administration 
site conditions. These ADRs accounted for two thirds of the total number of perceived ADRs. One 
reason for such a clustering may be that the ADRs in our study were reported by the children’s parents 
or the children themselves. It may be easier for them, as non-professionals, to perceive such ADRs. 
Our study sample consisted of non-institutionalized children in outpatient care; serious ADRs needing 
hospitalization may therefore have been excluded in advance. In addition, ADRs such as 
hepatotoxicity and pathological laboratory abnormalities induced by drug use were less likely to be 
reported in such a survey. Though we did not assess the severity of perceived ADRs,we presumed 
that most of the patients-perceived ADRs were mild to moderate and possibly at the lower limits of the 
range usually reported.Intensified ADR monitoring may identify a higher number of ADRs and more 
severe ADRs. However, this would require personnel and involve the cost of medical examinations 
[20].  
 
Perceived ADRs were reported most frequently in relation to drugs acting on the nervous system, 
systemic anti-infectives, drugs acting on the respiratory system, genito-urinary and sex hormones, 
  
dermatologicals, and drugs acting on alimentary system and metabolism.Medicines from these 
classes were also the paediatric medicines that accounted for the vast majority of all medicines 
used. The prevalence rates of perceived ADRs varied between these classes.The lowest rate was 
found in drugs acting on the alimentary system and metabolism; in our study most of the medicines in 
this class were hydrosoluble vitamins and mineral supplements. In the class of drugs acting on the 
nervous system,suspected drugs were mainly those of the psychoanaleptics subgroup 
(methylphenidate in particular). Analgesics aspirin and paracetamol were reported less often,even 
though they accounted for a substantial proportion of the medicines in this class (data not shown). As 
for drugs acting on the respiratory system, perceived ADRs were mostly recorded in the subgroup 
of cough and cold medicines, the safety of which was recently reviewed by the UKMedicines and 
Healthcare products Regulatory Agency (MHRA),which called for their rational use and intensive 
monitoring [37]. 5.7% of all systemic anti-infectives were involved in the occurrence of perceived ADRs 
(mainly the antibiotics subgroup). Similar findings were also reported previously in both prospective 
studies [6] and the analysis of data from ADR spontaneous reporting [38], as well as in the pilot study 
on ADR monitoring among children by community pharmacies in Aberdeen, UK [39].  
 
Most medicines thatwere used regularlywere prescription medicines, which, as found in our study, 
were more likely to cause an ADR than OTC medicines. Interestingly, we found that medicines that 
were used for a medium period of time were more likely to cause an ADR. Repeated use of medicines 
for a medium period (from 1 week to 12 months) meant rechallenges and dechallenges, so it was easy 
for parents/adolescents to perceive any ADR. Longterm use of medicines over 1 year, however, may 
induce tolerance. In addition, patients may choose not to report what they may think is ‘normal’ when it 
occurs repeatedly. As a matter of fact, the characteristics of perceived ADRs relating to the suspected 
medicines and symptoms found in our study were very similar to those found by means of the yellow 
card system in Spain [38], among outpatient children in the Netherlands [40] and in the US [41], and in 
the regional ADR monitoring study conducted in Brandenburg, Germany [21]. A recent review 
revealed that the quality of patient ADR reports seemed not to differ very much from that of reports by 
health professionals [42].  
 
A major strength of our study is that we used population-representative data to collect and analyze the 
perceived ADRs among non-institutionalized children.The results provide a clear picture of the 
frequency and spectrum of perceived ADRs that were not necessarily related to medical treatment in 
hospitals or outpatient facilities. There are several limitations, however. First, the ADRs reported in this 
study were perceived by children’s parents or the patients themselves. It may be difficult for them to 
distinguish between an ADR and a symptom of the disease being treated, resulting in over- or under-
reporting. Second, although all perceived ADRs were documented and confirmed by medical 
professionals with medical knowledge, a standardized causality and severity assessment was not 
carried out. Nevertheless, since parents may understand their own children better and can observe 
their health status more closely and perceive any changes after the intake of medicines, parental 
reporting of perceived ADRs can be regarded as an effective method in paediatric pharmacovigilance 
[42, 43].Finally,drug use was measured in the past 7 days before the medical interview. This method is 
less likely to capture ADRs following longterm medicine use.  
 
In conclusion, the perceived ADRs in the generally healthy child population were clustered with 
gastrointestinal disorders and skin and subcutaneous tissue disorders. They appeared to be mild and 
at the lower limits of the range usually reported. This, however, should be interpreted in conjunction 
with methodological limitations.The results of the KiGGS survey on medicine use provided a significant 
contribution to the quantification of perceived ADRs in the general child population.A comparison of 
our findings with those of national and international studies suggests that health surveys covering a 
diverse range of drug use may be suitable for computing perceived ADR prevalence and identifying 
risk factors and should be taken into account together with other pharmacovigilance systems. This 
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Socio-demographic and health-related characteristics of survey participants by gender.German Health 
Interview and Examination Survey for Children and 



































Prevalence rates and risk factors of perceived ADRs among children who used medications.German 




*Adjusted for age group, gender, region, immigrant background, social status, number of drugs, parents-rated 






Perceived ADRs among children in Germany by origin of drugs, duration and frequency of use. 




*The amounts in each category may not add up to the total because of missing data. P value: chi-square test for 










Perceived ADRs among children in Germany by medication classes. German Health Interview and 




A00, Alimentary system and metabolism; B00, Blood and blood-forming organs; C00, Cardiovascular system; 
D00, Dermatologicals; G00, Genito-urinary system and sex hormones; G03A, Oral contraceptives; H00, Systemic 
hormonal preparations excluding sex hormones and insulin;J00, Anti-infectives for systemic use; J01, 
Antibiotics;L00, Antineoplastic and immunmodulating agents; M00, Musculoskeletal system; N00, Nervous 
system; N06, Psychoanaleptics; N06BA04, Methylphenidate 
(Ritalin); P00, Antiparasitic products, insecticides and repellents; R00, Respiratory system; R05, Cough and cold 

























Perceived ADRs among children in Germany by ATC classes and MedDRA SOC. German Health 




MedDRA SOC: 1 General disorders and administration site conditions; 2 Skin and subcutaneous tissue disorders; 
3 Respiratory, thoracic and mediastinal disorders; 4 Reproductive system and breast disorders; 5 Gastrointestinal 
disorders; 6 Immune system disorders; 7 Nervous system disorders; 8 Infections and infestations; 9 Psychiatric 
disorders; 10 Metabolism and nutrition disorders; 11 Others; 12 Not classified. ATC Codes: A00, Alimentary 
system and metabolism; B00, Blood and blood-forming organs; C00, Cardiovascular system; D00, 
Dermatologicals; G00, Genito-urinary system and sex hormones; H00, Systemic hormonal preparations excluding 
sex hormones and insulin; J00, Anti-infectives for systemic use; L00, Antineoplastic and immunmodulating 
agents; M00, Musculoskeletal system; N00, Nervous system; P00, Antiparasitic products, insecticides and 
repellents; R00, Respiratory system; S00, Sensory organs; V00, Various; Z00, Homoeopathics. 
ATC, Anatomical-Therapeutic-Chemical; MedDRA, Medical Dictionary for Regulatory Activities; SOC, System 
Organ Class. 
  
